Tools / Targets TYK2: Non-receptor tyrosine-protein kinase TYK2 Non-membrane spanning protein tyrosine kinase involved in numerous cytokines and interferons signaling, which regulates cell growth, development, cell migration, innate and adaptive immunity.
Drugs that act on it : 7 Approved : 4 In phases 1 to 3 : 3 Sponsors : 7 Who is on it, and how far along Every drug ChEMBL records acting on TYK2, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Approved4 Ruxolitinib Ruxolitinib SponsorDamora Therapeutics ModalitySmall molecule ActionInhibitor Open trials194 Upadacitinib Upadacitinib SponsorAbbVie ModalitySmall molecule ActionInhibitor Open trials91 Filgotinib Filgotinib SponsorAlfasigma ModalitySmall molecule ActionInhibitor Open trials14 Cravacitinib Cravacitinib SponsorBristol-Myers Squibb ModalitySmall molecule ActionNegative allosteric modulator Open trials0 Phase 31 Brepocitinib Brepocitinib SponsorPriovant Therapeutics ModalitySmall molecule ActionInhibitor Open trials3 Phase 22 Cerdulatinib Cerdulatinib SponsorDermavant Sciences GmbH ModalitySmall molecule ActionInhibitor Open trials0 Ropsacitinib Ropsacitinib SponsorPfizer ModalitySmall molecule ActionInhibitor Open trials0
The landscape Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 6 of 7 act as: Tyrosine-protein kinase TYK2 inhibitor; the rest name their own mechanism.
Open trials The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 27 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted A Study to Evaluate the Safety and Efficacy (How Well the Study Treatment Works) of ABBV-2294 in Adult Participants With Systemic Sclerosis That Are Currently Receiving Local Standard of Care Treatment, and to Determine the Best Dose of ABBV-2294 to be Evaluated Further. Upadacitinib Phase 2 / Phase 3 Not yet recruiting AbbVie Nov 12, 2026 Jaktinib in Ruxolitinib-Treatment Failure Myelofibrosis: A Multicenter, Prospective, Real-World Observational Study Ruxolitinib — Not yet recruiting Affiliated Hospital of Nantong University Nov 9, 2026 A Study of LBP-MARCO and Ruxolitinib in People With Graft-Versus-Host Disease (GVHD) Ruxolitinib Phase 1 Recruiting Memorial Sloan Kettering Cancer Center Nov 3, 2026 Topical Ruxolitinib Versus Tacrolimus With Excimer Laser for Localized Vitiligo Ruxolitinib Not applicable Enrolling by invitation Kafrelsheikh University Nov 2, 2026 ADBest TREAT Registry Upadacitinib — Recruiting Universitätsklinikum Hamburg-Eppendorf Oct 29, 2026 Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis Upadacitinib Phase 2 Not yet recruiting AbbVie Oct 29, 2026 A Study to Learn How Effective, Safe, and Tolerable Upadacitinib is for Young Participants With Non-segmental Vitiligo Upadacitinib Phase 3 Not yet recruiting AbbVie Oct 27, 2026 A Study to Learn About the Study Medicine Abrocitinib in People With Severe Atopic Dermatitis Who Have Switched From Other Therapies Upadacitinib — Not yet recruiting Pfizer Oct 21, 2026 A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms Ruxolitinib Phase 1 Recruiting Damora Therapeutics Sep 30, 2026 A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult Volunteers Upadacitinib Phase 1 Recruiting AbbVie Sep 28, 2026 Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial Ruxolitinib Phase 2 Not yet recruiting University Hospital, Basel, Switzerland Sep 25, 2026 Evaluating Safety ,Tolerability, Pharmacokinetic,Efficacy of WJ01024 or WJ01024 Combined With Ruxolitinib in Patients With Myelofibrosis Ruxolitinib Phase 1 Recruiting Henan Cancer Hospital Sep 3, 2026 Topical Ruxolitinib in Acute Skin GVHD (Graft Versus Host Disease) Ruxolitinib Phase 1 Not yet recruiting Children's Hospital Medical Center, Cincinnati Sep 3, 2026 Sirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNI Ruxolitinib Phase 1 / Phase 2 Not yet recruiting Peking University People's Hospital Sep 1, 2026 An Interventional Study of Upadacitinib Extended-Release Tablets in Patients With Refractory Uveitis Upadacitinib Phase 4 Active, not recruiting Tianjin Medical University Aug 19, 2026 A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata Upadacitinib Phase 3 Recruiting AbbVie Aug 19, 2026 FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial Filgotinib Phase 4 Not yet recruiting University Hospital, Clermont-Ferrand May 8, 2026 Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents Filgotinib Phase 3 Recruiting Alfasigma S.p.A. Apr 28, 2026 OLE Study With Filgotinib in JIA Filgotinib Phase 3 Recruiting Alfasigma S.p.A. Apr 27, 2026 A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris Brepocitinib Phase 2 / Phase 3 Recruiting Priovant Therapeutics, Inc. Apr 16, 2026 A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis Brepocitinib Phase 2 / Phase 3 Recruiting Priovant Therapeutics, Inc. May 18, 2025 A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice Filgotinib Phase 4 Active, not recruiting Eisai Korea Inc. May 9, 2025 A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis Filgotinib Phase 3 Recruiting Alfasigma S.p.A. Mar 7, 2025 JAK Inhibitor Dose TAPering Strategy Study Filgotinib Phase 4 Recruiting University Hospital, Toulouse Nov 13, 2024 A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis Brepocitinib Phase 3 Active, not recruiting Priovant Therapeutics, Inc. May 28, 2024 Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases Filgotinib Phase 2 Recruiting UMC Utrecht Feb 29, 2024 A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants Filgotinib — Recruiting Eisai Korea Inc. Feb 7, 2024
Show all 27Diseases most associated with it Open Targets association score, 0 to 1; all associations
Immunodeficiency 35 0.75
Psoriasis vulgaris 0.72
Crohn disease 0.69
Atopic eczema 0.59
Type 1 diabetes mellitus 0.58
Hypothyroidism 0.58
Genes and related targets Complexes and families that share a gene with this target
Genes TYK2 Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3553 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-18. Gene name, function (UniProt P29597 , CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets